Today’s reality
Why haven’t success rates of treatment innovations improved?
Finding safe, effective, and commercially viable treatment innovations is a complex, intensive process that requires analyzing vast amounts of data. Yet, critical decisions remain challenging. The full potential of data and insights remains widely untapped to avoid costly failures and identify the right path forward.
The current trajectory is unsustainable: R&D costs continue to climb without corresponding gains in success rates.
At Insira, we find this reality unacceptable.
88%
of drugs starting Phase 1 fail to reach the market
Source: CMR Global R&D Programme
Up to 78%
of launched drugs miss their revenue forecast in the first 2 years
Source: McKinsey










